Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Aytu BioPharma Inc (AYTU)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$1.81-5.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.27 → 0.27 EPS · FY ending Jun 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for AYTU yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating loss improves to at least -$4.06 million in Q3 2026 | Aytu BioPharma is improving its operating income, reducing losses from $7.62 million to $4.06 million. | Intact | Operating loss worsens beyond -$4.06 million in 2026-Q3 | Operating income: $-777,000 FY2026-Q4; GAAP. Published target: >= -$4.06 million. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 22, 2026-777,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, small-cap healthcare business with a turnaround-like earnings profile, not a proven durable compounder. The long-term thesis is in a watch state: EXXUA and legacy-product revenue improved sequentially, but the company remains loss-making on a full-year adjusted EBITDA basis.
AYTU is tagged as cheap versus peers, but the valuation model has low confidence and the expectations gap is negative, suggesting current expectations may still be ahead of the evidence. The priced-in assessment is marked justified, with low fragility, so the snapshot does not point to a clear mismatch between valuation and expectations.
Near term, the latest quarter showed higher EXXUA, ADHD, and Pediatric revenue, lower operating expenses, and adjusted EBITDA improving to a small positive result. However, fiscal 2026 adjusted EBITDA remained negative, and recent performance still sits below its industry cohort; the next guidance update is a key risk. Over the multi-year view, consistent positive adjusted EBITDA depends on maintaining cost control while growing EXXUA and the legacy portfolio.
The favorable case depends on continued EXXUA prescription and revenue growth, stronger legacy-product performance, and sustained expense discipline. The unfavorable case includes weaker guidance or a worsening jobs backdrop, while continued earnings strength from healthcare peers could support the sector context. Evidence for the broader forward scenarios is limited.
Over the next 1 to 3 years, AYTU’s thesis hinges on turning recent sequential progress into consistent positive earnings, with elevated risk and below-cohort performance still unresolved. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Strong adoption of EXXUA product | The company has strong adoption of its EXXUA product, supporting revenue growth. | Intact | Adoption of EXXUA weakens or declines materially | Qualitative: Strong adoption confirmed Q4 FY26 earnings beat driven by EXXUA momentum; Q3 highlights noted strong adoption; no evidence of decline. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue at or above $13.9 million in Q3 2026 | A primary condition in Aytu BioPharma Inc's published investment case. The stated target is >= $13.9 million. | Intact | Revenue falls below $13.9 million in 2026-Q3 | Revenue: $16.106M FY2026-Q4; GAAP. Published target: >= $13.9 million. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 22, 202616,106,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.05 → $0.27 · observed estimates
$0.09B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-25 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-26 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-27 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-28 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-29 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-30 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-07-31 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-01 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-02 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-03 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-04 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-05 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-06 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-07 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-08 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-09 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-10 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-11 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-12 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-13 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-14 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-15 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-16 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-17 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-18 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-19 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-20 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-21 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-22 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-23 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-24 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-25 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-26 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-27 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-28 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-29 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-30 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-08-31 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-01 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-02 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-03 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-04 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-05 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-06 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-07 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-08 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-09 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-10 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-11 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-12 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-13 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-14 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-15 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-16 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-17 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-18 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-19 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-20 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-21 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-22 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-23 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-24 | $1.05 | $94,499,000 | 1 / 1 |
| 2026-09-25 | $0.34 | $92,362,000 | 1 / 2 |
| 2026-09-26 | $0.34 | $92,362,000 | 1 / 2 |
| 2026-09-27 | $0.34 | $92,362,000 | 1 / 2 |
| 2026-09-28 | $0.34 | $92,362,000 | 1 / 2 |
| 2026-09-29 | $0.34 | $92,362,000 | 1 / 2 |
| 2026-09-30 | $0.34 | $92,362,000 | 1 / 2 |
| 2026-10-01 | $0.27 | $86,908,000 | 2 / 2 |
| 2026-10-02 | $0.27 | $86,908,000 | 2 / 3 |
| 2026-10-03 | $0.27 | $86,908,000 | 2 / 3 |
| 2026-10-04 | $0.27 | $86,908,000 | 1 / 3 |
| 2026-10-05 | $0.27 | $86,908,000 | 1 / 3 |
| 2026-10-06 | $0.27 | $86,908,000 | 1 / 3 |
| 2026-10-07 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-08 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-09 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-10 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-11 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-12 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-13 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-14 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-15 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-16 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-17 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-18 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-19 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-20 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-21 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-22 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-23 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-24 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-25 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-26 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-27 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-28 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-29 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-30 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-10-31 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-11-01 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-11-02 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-11-03 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-11-04 | $0.27 | $86,908,000 | 1 / 2 |
| 2026-11-05 | $0.27 | $86,908,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.